Morgan Stanley Downgrades Karuna Therapeutics to Equal-Weight, Raises Price Target to $330
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has downgraded Karuna Therapeutics (NASDAQ:KRTX) from Overweight to Equal-Weight, while also raising the price target from $295 to $330.

December 22, 2023 | 4:53 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Karuna Therapeutics was downgraded by Morgan Stanley from Overweight to Equal-Weight, although the price target was raised from $295 to $330.
The downgrade to Equal-Weight suggests that Morgan Stanley believes Karuna Therapeutics is now fairly valued and may not provide the same level of outperformance as suggested by the previous Overweight rating. However, the increase in the price target indicates a belief that the stock still has potential to grow, albeit at a more moderate pace. This mixed signal could lead to a neutral short-term impact on the stock price as investors digest both the downgrade and the raised price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100